More than ancillary: HIV social services, intermediate outcomes and quality of life.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 20024705)

Published in AIDS Care on October 01, 2009

Authors

John J Chin1, Michael Botsko, Elana Behar, Ruth Finkelstein

Author Affiliations

1: Department of Urban Affairs and Planning, Hunter College of the City University of New York, New York, NY, USA. john.chin@hunter.cuny.edu

Articles by these authors

Abscisic acid inhibits type 2C protein phosphatases via the PYR/PYL family of START proteins. Science (2009) 10.21

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97

Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat (2008) 1.89

Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr (2011) 1.52

The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care (2006) 1.39

A vulnerable population in a time of crisis: drug users and the attacks on the World Trade Center. J Urban Health (2002) 1.30

Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. J Acquir Immune Defic Syndr (2003) 1.29

Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med (2010) 1.27

Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis (2006) 1.19

Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr (2011) 1.17

A small plant-specific protein family of ABI five binding proteins (AFPs) regulates stress response in germinating Arabidopsis seeds and seedlings. Plant Mol Biol (2008) 1.14

Roundtable on Urban Living Environment Research (RULER). J Urban Health (2011) 1.14

The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. J Acquir Immune Defic Syndr (2011) 1.14

Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr (2011) 1.10

Access to multilingual medication instructions at New York City pharmacies. J Urban Health (2007) 1.10

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 1.09

Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr (2011) 1.09

Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. AIDS Care (2009) 1.07

Predictors of day-level sexual risk for young gay and bisexual men. AIDS Behav (2013) 1.02

Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr (2011) 1.02

Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend (2008) 1.00

Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr (2011) 0.94

Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men. AIDS Behav (2013) 0.92

Civic/sanctuary orientation and HIV involvement among Chinese immigrant religious institutions in New York City. Glob Public Health (2011) 0.90

The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 0.90

Aging without Medicare? Evidence from New York City. Inquiry (2006) 0.88

Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. J Acquir Immune Defic Syndr (2011) 0.87

Adherence to HAART: perspectives from clients in treatment support programs. Psychol Health Med (2006) 0.81

The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. J Acquir Immune Defic Syndr (2011) 0.81

Correlation of a brief perceived stress measure with nonadherence to antiretroviral therapy over time. J Acquir Immune Defic Syndr (2005) 0.80

Faith-Based HIV Care and Prevention in Chinese Immigrant Communities: Rhetoric or Reality? J Psychol Theol (2011) 0.78

Influences of stigma and HIV transmission knowledge on member support for faith-placed HIV initiatives in Chinese immigrant Buddhist and protestant religious institutions in New York City. AIDS Educ Prev (2013) 0.75

Evaluating community-based prevention programs. J Urban Health (2009) 0.75